Anti-PD-L1 cancer immunotherapy antibodies
US12391758B2 · kind B2 · utility
0Cited by
2References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 20, 2019 |
| Grant date | Aug 19, 2025 |
| Priority date | — |
| Expiry date | Jan 20, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are compositions and methods relating to or derived from anti-PD-L1 antibodies with ADCC and/or CDC activities. More specifically, provided are fully human antibodies that bind PD-L1, PD-L1-binding antibody fragments, derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.